SARS-CoV-2 vaccines in development

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Origin and evolution of pathogenic coronaviruses

Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

Bayarri‐Olmos, R., Jarlhelt, I., Johnsen, L. B., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Matthiesen, F., Nielsen, S. D., Iversen, K. K., Ostrowski, S. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757197 · Cited by 25

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 25

Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?

Joshi, G., Borah, P., Thakur, S., Sharma, P., Mayank, M., & Ramarao, P. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1995283 · Cited by 28

Vaccines 2020: The era of the digital vaccine is here

Pizza, M., Pecetta, S., & Rappuoli, R. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3249 · Cited by 25

mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2

Jin, Y., Hou, C., Li, Y., Zheng, K., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.821538 · Cited by 24

Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article

Saied, A. A., Metwally, A. A., Alobo, M., Shah, J., Sharun, K., & Dhama, K. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106233 · Cited by 25

The COVID-19 vaccination acceptance/hesitancy rate and its determinants among healthcare workers of 91 Countries: A multicenter cross-sectional study.

Askarian, M., Semenov, A., Llopis, F., Rubulotta, F. M., Dragovac, G., Pshenichnaya, N. Y., Assadian, O., Ruch, Y., Shayan, Z., Fortunatti, C. P., et al. (2021) · EXCLI journal · doi:10.17179/excli2021-4439 · Cited by 28

Aptamers as promising nanotheranostic tools in the COVID ‐19 pandemic era

Dzuvor, C. K. O., Tettey, E. L., & Danquah, M. K. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1785 · Cited by 24

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

Junker, D., Dulovic, A., Becker, M., Wagner, T. R., Kaiser, P. D., Traenkle, B., Kienzle, K., Bunk, S., Struemper, C., Haeberle, H. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10987-2 · Cited by 25

Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2

Lai, Y., Cheng, Y., Chao, C.-H., Chang, Y., Chen, C.-D., Tsai, W., Wang, S., Lin, Y., Chang, C., Chuang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868724 · Cited by 26

Considerations for Novel COVID-19 Mucosal Vaccine Development

Alturaiki, W. (2022) · Vaccines · doi:10.3390/vaccines10081173 · Cited by 25

Visual Detection of COVID-19 from Materials Aspect

Wang, G., Wang, L., Meng, Z., Su, X., Jia, C., Qiao, X., Pan, S., Chen, Y., Cheng, Y., & Zhu, M. (2022) · Advanced Fiber Materials · doi:10.1007/s42765-022-00179-y · Cited by 25

The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine

Haq, I. U., Krukiewicz, K., Yahya, G., Haq, M. U., Maryam, S., Mosbah, R., Saber, S., & Alrouji, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021536 · Cited by 26

Hyper‐inflammation and complement in COVID ‐19

Pires, B. G., & Calado, R. T. (2023) · American Journal of Hematology · doi:10.1002/ajh.26746 · Cited by 27

In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants

Tran, H. T. T., Le, N. P. K., Gigl, M., Dawid, C., & Lamy, E. (2021) · Pharmaceuticals · doi:10.3390/ph14101055 · Cited by 28

Age-targeted dose allocation can halve COVID-19 vaccine requirementsPreprint

Meehan, M. T., Cocks, D., Caldwell, J. M., Trauer, J. M., Adekunle, A. I., Ragonnet, R. R., & McBryde, E. S. (2020) · medRxiv · doi:10.1101/2020.10.08.20208108 · Cited by 28

Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in MexicoPreprint

Ponce‐de‐León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán‐Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., et al. (2022) · medRxiv · doi:10.1101/2022.02.08.22270676 · Cited by 25

Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant

Zhang, W., Huang, L., Ye, G., Geng, Q., Ikeogu, N., Harris, M., Dileepan, G., Burrack, K. S., Du, L., Frosch, A. E. P., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00837-6 · Cited by 25

Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening

Wilders, H., Biggs, G. S., Rowe, S. M., Cawood, E. E., Riziotis, I. G., Rendina, A. R., Grant, E. K., Pettinger, J., Fallon, D. J., Skehel, M. J., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202418314 · Cited by 28

Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19

Dhodapkar, M. V., Dhodapkar, K. M., & Ahmed, R. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0177 · Cited by 24

SARS-CoV-2 vaccines: fast track versus efficacy

Alkandari, D., Herbert, J. A., Alkhalaf, M. A., Yates, C., & Panagiotou, S. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00034-3 · Cited by 23

Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions

Shah, M., & Woo, H. G. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0026 · Cited by 23

Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design

Rezaei, S., Sefidbakht, Y., & Uskoković, V. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab241 · Cited by 24

Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review

Imai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 21

Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review

Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 26

Vaccine-Induced Cellular Immunity against Bordetella pertussis: Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines

Saso, A., Kampmann, B., & Roetynck, S. (2021) · Vaccines · doi:10.3390/vaccines9080877 · Cited by 24

Inhalable hydrophilic molecule-loaded liposomal dry powder formulations using supercritical CO2 – assisted spray-drying

Costa, C., Nobre, B. C. O., Matos, A. S., Silva, A. S., Casimiro, T., Corvo, M. L., & Aguiar‐Ricardo, A. (2021) · Journal of CO2 Utilization · doi:10.1016/j.jcou.2021.101709 · Cited by 24

COVID-19 Transcriptomic Atlas: A Comprehensive Analysis of COVID-19 Related Transcriptomics Datasets

Alqutami, F., Senok, A. C., & Hachim, M. Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.755222 · Cited by 27

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera

Yahalom-Ronen, Y., Noam Erez, A., Fisher, M., Tamir, H., Politi, B., Achdout, H., Melamed, S., Glinert, I., Weiss, S., Cohen-Gihon, I., et al. (2022) · Vaccines · doi:10.3390/vaccines10020291 · Cited by 22

Vaccines against SARS-CoV-2 variants and future pandemics

Park, T., Hwang, H., Moon, S., Kang, S. G., Song, S., Kim, Y. H., Kim, H., Ko, E., Yoon, S., Kang, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2110075 · Cited by 23

Safety surveillance and challenges in accelerated COVID-19 vaccine development

Cole, A., Webster, P. S., Liew, D. V., Salas, M., Aimer, O., & Malikova, M. A. (2022) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986221116452 · Cited by 25

The Coming of Age of Nucleic Acid Vaccines during COVID-19

Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 30

COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore

Tan, W. C., Tan, J. Y. J., Lim, J. S. J., Tan, R. S. Y. C., Lee, A. R. Y. B., Leong, F. L., Lee, S. C., Chai, L. Y. A., Tan, T. T., Malek, M. I. B. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2271 · Cited by 23

Ambient Temperature Stable, Scalable COVID‐19 Polymer Particle Vaccines Induce Protective Immunity

Chen, S., Evert, B. J., Adeniyi, A., Salla‐Martret, M., Lua, L. H. L., Ozberk, V., Pandey, M., Good, M. F., Suhrbier, A., Halfmann, P., et al. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202102089 · Cited by 24

Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in micePreprint

Polak, K., Greze, N., Lachat, M., Merle, D., Chiumento, S., Bertrand‐Gaday, C., Trentin, B., & Mamoun, R. Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.28.357137 · Cited by 24

A unified evolution-driven deep learning framework for virus variation driver prediction

Nie, Z., Liu, X., Chen, J., Wang, Z., Liu, Y., Si, H.-R., Dong, T., Xu, F., Song, G., Wang, Y., et al. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-024-00966-9 · Cited by 25

All eyes on a hurdle race for a SARS-CoV-2 vaccine

Gaebler, C., & Nussenzweig, M. C. (2020) · Nature · doi:10.1038/d41586-020-02926-w · Cited by 24

The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy

Santopolo, S., Riccio, A., & Santoro, M. G. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.080 · Cited by 23

Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters

Zhugunissov, K. D., Zakarya, K. D., Khairullin, B. M., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M., Sultankulova, K. T., Kerimbayev, A. A., Nurabayev, S. S., Myrzakhmetova, B. S., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.720437 · Cited by 26

Microorganisms as Shapers of Human Civilization, from Pandemics to Even Our Genomes: Villains or Friends? A Historical Approach

Rodríguez‐Frias, F., Quer, J., Tabernero, D., Cortese, M. F., García-García, S., Rando‐Segura, A., & Pumarola, T. (2021) · Microorganisms · doi:10.3390/microorganisms9122518 · Cited by 26

An overview of the ongoing challenges in SARS-CoV-2 global control

Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24

A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD

Wang, X., Hu, A., Chen, X., Zhang, Y., Yu, F., Yue, S., Li, A., Zhang, J., Pan, Z., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00954-8 · Cited by 23

Small‐Molecule Quenchers for Förster Resonance Energy Transfer: Structure, Mechanism, and Applications

Fang, B., Shen, Y., Peng, B., Bai, H., Wang, L., Zhang, J., Hu, W., Fu, L., Zhang, W., Li, L., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202207188 · Cited by 23

Public Health Management of the COVID-19 Pandemic in Australia: The Role of the Morrison Government

Duckett, S. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610400 · Cited by 22

Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins

O’Donnell, K. L., Gourdine, T., Fletcher, P., Clancy, C. S., & Marzi, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025500 · Cited by 22

COVID-19 Vaccine Hesitancy among Pregnant Women Attending Antenatal Clinics in Pakistan: A Multicentric, Prospective, Survey-Based Study

Mustafa, Z. U., Bashir, S., Shahid, A., Raees, I., Salman, M., Merchant, H. A., Aldeyab, M. A., Kow, C. S., & Hasan, S. S. (2022) · Viruses · doi:10.3390/v14112344 · Cited by 171

An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination

Carreño, J. M., Raskin, A. J., Singh, G., Tcheou, J., Kawabata, H., Gleason, C., Srivastava, K., Vigdorovich, V. I., Dambrauskas, N., Gupta, S. L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2847 · Cited by 24

Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential

Ayoup, M. S., ElShafey, M. M., Abdel‐Hamid, H., Ghareeb, D. A., Abu-Serie, M. M., Heikal, L., & Teleb, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115272 · Cited by 23

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 24

Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT™ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice

Lai, C.-Y., To, A., Wong, T. A. S., Lieberman, M. M., Clements, D. E., Senda, J. T., Ball, A. H., Pessaint, L., Andersen, H., Furuyama, W., et al. (2021) · Vaccine X · doi:10.1016/j.jvacx.2021.100126 · Cited by 24

Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward

Vashishtha, V. M., & Kumar, P. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1845524 · Cited by 22

An intra-host SARS-CoV-2 dynamics model to assess testing and quarantine strategies for incoming travelers, contact management, and de-isolation

van der Toorn, W., Oh, D., Bourquain, D. R., Michel, J., Krause, E., Nitsche, A., & von Kleist, M. (2021) · Patterns · doi:10.1016/j.patter.2021.100262 · Cited by 21

Animal Coronavirus Diseases: Parallels with COVID-19 in Humans

Lin, C., Chan, K. R., Ooi, E. E., Chiou, M., Minh, H. V., Hsueh, P., & Ooi, P. T. (2021) · Viruses · doi:10.3390/v13081507 · Cited by 22

Isolation of Antibodies Against the Spike Protein of SARS-CoV from Pig Serum for Competitive Immunoassay

Jung, J., Bong, J.-H., Kim, T. H., Sung, J. S., Lee, C., Kang, M., Kim, H. O., Shin, H., & Pyun, J. (2021) · BioChip Journal · doi:10.1007/s13206-021-00033-0 · Cited by 22

Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations

Vardhan, S., & Sahoo, S. K. (2021) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2021.12.002 · Cited by 22

Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants

Masuda, A., Lee, J. M., Miyata, T., Mon, H., Sato, K., Oyama, K., Sakurai, Y., Yasuda, J., Takahashi, D., Ueda, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803647 · Cited by 21

The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study

Perkmann, T., Mucher, P., Perkmann‐Nagele, N., Radakovics, A., Repl, M., Köller, T., Schmetterer, K. G., Bigenzahn, J. W., Leitner, F., Jordakieva, G., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01402-21 · Cited by 22

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

Karbiener, M., Farcet, M. R., Zollner, A., Masuda, T., Mori, M., Moschen, A. R., & Kreil, T. R. (2022) · npj Vaccines · doi:10.1038/s41541-022-00455-3 · Cited by 20

CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity

Long, Y., Sun, J., Song, T., Liu, T., Tang, F., Zhang, X., Ding, L., Miao, Y., Zhu, W., Pan, X., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00370-2 · Cited by 22

Addressing COVID-19 vaccine hesitancy

Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 22

The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses

Muhar, B. K., Nehira, J., Malhotra, A., & Kotchoni, S. O. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221097248 · Cited by 24

Short-Term Side Effects and SARS-CoV-2 Infection after COVID-19 Pfizer–BioNTech Vaccine in Children Aged 5–11 Years: An Italian Real-World Study

Capponi, M., Pulvirenti, F., Cinicola, B. L., Brindisi, G., Conti, M. G., Colaiocco, G., Castro, G. D., Guido, C. A., Duse, M., Midulla, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10071056 · Cited by 21

Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review

Kreuzberger, N., Hirsch, C., Andreas, M., Böhm, L., Bröckelmann, P. J., Cristanziano, V. D., Golinski, M., Hausinger, R. I., Mellinghoff, S. C., Lange, B., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015021 · Cited by 22

Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters

Liu, S., Stauft, C. B., Selvaraj, P., Chandrasekaran, P., D’Agnillo, F., Chou, C., Wu, W. W., Lien, C. Z., Meseda, C. A., Pedro, C. L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34571-4 · Cited by 21

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19

Hersi, F., Sebastian, A., Tarazi, H., Srinivasulu, V., Mostafa, A., Allayeh, A. K., Zeng, C., Hachim, I. Y., Liu, S., Abu‐Yousef, I. A., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115380 · Cited by 24

Sublingual Dissolving Microneedle (SLDMN)‐Based Vaccine for Inducing Mucosal Immunity against SARS‐CoV‐2

Kim, Y.-S., Park, I. H., Shin, J., Choi, J., Jeon, C., Jeon, S., Shin, J., & Jung, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300889 · Cited by 22

SARS-CoV-2 spike-specific regulatory T cells (Treg) expand and develop memory in vaccine recipients suggesting a role for immune regulation in preventing severe symptoms in COVID-19

Franco, A., Song, J., Chambers, C., Sette, A., & Grifoni, A. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2259133 · Cited by 23

Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19

Jarai, B. M., Stillman, Z. S., Bomb, K., Kloxin, A. M., & Fromen, C. A. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01287 · Cited by 22

From Bulk to Nanoparticles: An Overview of Antiviral Materials, Its Mechanisms, and Applications

Rodrigues, I. C. P., Campo, K. N., Arns, C. W., Gabriel, L. P., Webster, T. J., & Lopes, É. S. N. (2021) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202100044 · Cited by 22

COVID-19 clinical presentation, management, and epidemiology: a concise compendium

Maison, D. P., Tasissa, H., Deitchman, A. N., Peluso, M. J., Deng, Y., Miller, F. D., Henrich, T. J., & Gerschenson, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1498445 · Cited by 26

Coronavirus infections in childhood and vaccine studies

Aygün, D., Önal, P., Apaydın, G., & Çokuğraş, H. C. (2020) · Turkish Archives of Pediatrics · doi:10.5152/turkarchpediatr.2020.20255 · Cited by 23

An update to “novel therapeutic approaches for treatment of COVID-19”

Hossein‐Khannazer, N., Shokoohian, B., Shpichka, A. I., Aghdaei, H. A., Timashev, P. S., & Vosough, M. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02027-1 · Cited by 21

Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing

Mahalingam, S., Peter, J., Xu, Z., Bordoloi, D., Ho, M., Kalyanaraman, V. S., Srinivasan, A., & Muthumani, K. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06836 · Cited by 20

Challenges and Issues of Anti-SARS-CoV-2 Vaccines

Blumental, S., & Debré, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.664179 · Cited by 22

A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene

Daniels, R. S., Harvey, R., Ermetal, B., Xiang, Z., Galiano, M., Adams, L., & McCauley, J. W. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12892 · Cited by 21

The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview

Mouhoub, E., Domenech, P., Ndao, M., & Reed, M. B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.757858 · Cited by 21

Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly

Meyer‐Arndt, L., Schwarz, T., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Gürcan, K., Uyar‐Aydin, Z., Müller, M. A., Drosten, C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100990 · Cited by 20

Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine

Shulman, R. M., Weinberg, D. S., Ross, E. A., Ruth, K. J., Rall, G. F., Olszanski, A. J., Helstrom, J. L., Hall, M. J., Judd, J., Chen, D. Y. T., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7113 · Cited by 21

Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding

Bozdaganyan, M. E., Sokolova, O. S., Шайтан, К. В., Kirpichnikov, M. P., & Orekhov, P. S. (2022) · Viruses · doi:10.3390/v14020295 · Cited by 20

Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern

Xie, T., Lu, S., He, Z., Liu, H., Wang, J., Tang, C., Yang, T., Yu, W., Li, H., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00920-4 · Cited by 20

Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses

Klasse, P. J., & Moore, J. P. (2022) · Journal of Virology · doi:10.1128/jvi.00034-22 · Cited by 23

Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2

Cao, H., Mai, J., Zhou, Z. P., Li, Z., Duan, R. C., Watt, J., Chen, Z., Bandara, R. A., Li, M., Ahn, S. K., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00723-0 · Cited by 22

Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes

Diebold, O., Gonzalez, V., Venditti, L., Sharp, C., Blake, R., Tan, W. S., Stevens, J. M., Caddy, S., Digard, P., Borodavka, A., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00488-22 · Cited by 20

Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles

Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 21

Publication trends of research on COVID-19 and host immune response: A bibliometric analysis

Xia, Y. Q., Yao, R.-Q., Zhao, P., Tao, Z., Zheng, L., Zhou, H., Yao, Y.-M., & Song, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.939053 · Cited by 22

Application of Traditional Vaccine Development Strategies to SARS-CoV-2

Rando, H. M., Lordan, R., Lee, A. J., Naik, A. S., Wellhausen, N., Sell, E., Kolla, L., Gitter, A., Greene, C. S., Bansal, V., et al. (2023) · mSystems · doi:10.1128/msystems.00927-22 · Cited by 22

Developing Next‐Generation Protein‐Based Vaccines Using High‐Affinity Glycan Ligand‐Decorated Glyconanoparticles

Gao, Y., Wang, W., Yang, Y., Zhao, Q., Yang, C., Jia, X., Liu, Y., Zhou, M., Zeng, W., Huang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202204598 · Cited by 21

Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma

Simon, S. M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00554-w · Cited by 21

Advances in immunological and theranostic approaches of gold nanoparticles – A review

Sarangi, M. K., Padhi, S. K., Rath, G., Nanda, S. S., & Yi, D. K. (2023) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2023.110858 · Cited by 22

SARS-CoV-2 infection exacerbates the cellular pathology of Parkinson’s disease in human dopaminergic neurons and a mouse model

Lee, B., Choi, H. N., Hyun, Y. S., Ko, M., Seong, H., Jo, M. G., Kim, S., Song, C., Yoon, S., Choi, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101570 · Cited by 24

Therapeutic vaccine for chronic diseases after the COVID-19 Era

Nakagami, H., Hayashi, H., Shimamura, M., Rakugi, H., & Morishita, R. (2021) · Hypertension Research · doi:10.1038/s41440-021-00677-3 · Cited by 22

Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2

Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 22

Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

Kyei-Barffour, I., Akwetey, S. A., Aninagyei, E., Ghartey‐Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112282 · Cited by 21

What do we know about the function of SARS-CoV-2 proteins?

Arévalo, S. J., Chávez, A. C., Calampa, C. S. U., Sifuentes, D. Z., Huallpa, C. J., Bianchi, G. L., Casas, R. G.-S., Aguilar, M. Q., & Pineda, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1249607 · Cited by 23

COVID-19 Vaccine

Fernandes, A., Chaudhari, S., Jamil, N., & Gopalakrishnan, G. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.013 · Cited by 19

Advances of nanomaterials‐based strategies for fighting against COVID‐19

Zeng, C., Hou, X., Bohmer, M., & Dong, Y. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200180 · Cited by 19

Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (CoVRapid CL-MIA)

Klüpfel, J., Koros, R. C., Dehne, K., Ungerer, M., Würstle, S. M., Mautner, J., Feuerherd, M., Protzer, U., Hayden, O., Elsner, M., et al. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03315-6 · Cited by 20

Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters

Kulkarni, R., Chen, W.-C., Lee, Y., Kao, C., Hu, S.-L., Ma, H., Jan, J., Liao, C., Liang, J., Ko, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257191 · Cited by 21

Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs

Jones, L. P., Bakre, A. A., Naikare, H. K., Kolhe, R. B., Sánchez, S., Mosley, Y. C., & Tripp, R. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257563 · Cited by 20

Nanoscience versus Viruses: The SARS‐CoV‐2 Case

Gościańska, J., Freund, R., & Wuttke, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107826 · Cited by 21

Viral Vaccines and Current Status of Vaccine Developing Studies Against Novel SARS Coronavirus-2

Keşli, R. (2020) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2020.84755

SARS-CoV-2 Vaccine Development: An Overview and Perspectives

Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40

Phase III Vaccines for SARS-CoV-2: A Review of Development and Available Data

Ehsan, H. S. A., Sana, M. K., Sarwar, A., Hanif, N., & Khan, S. R. (2020) · Internal Medicine Review · doi:10.18103/imr.v6i5.905

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Alturki, S. O., Alturki, S. O., Connors, J. R., Cusimano, G. M., Kutzler, M. A., Izmirly, A. M., & Haddad, E. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01880 · Cited by 80

Latest in COVID-19 Vaccine 'Candidates' Race

Atoum, M. F. M., Zreig, D. A., & Zreig, L. M. A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220818124416